Business Context and Reporting Period
This Form 8-K Current Report was filed by Supernus Pharmaceuticals, Inc. on July 23, 2012, covering events occurring on July 20, 2012. The filing serves to disclose a significant executive appointment within the company's leadership structure.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current event disclosure and does not contain financial statements or performance metrics.
Material Changes
The primary material change reported is the appointment of Dr. Stefan Schwabe, MD, PhD, to the roles of Executive Vice-President of Research & Development and Chief Medical Officer.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, management commentary on future outlook, specific risk factors, or contingencies. The document focuses solely on the personnel change and incorporates a press release as an exhibit.
Key Facts for Investor Verification
- Dr. Stefan Schwabe has been appointed as Executive Vice-President of Research & Development and Chief Medical Officer.
- The appointment was announced via a press release dated July 20, 2012 (Exhibit 99.1).
- The report was signed by Gregory S. Patrick, Vice-President and Chief Financial Officer.
- No financial data or operational metrics are included in this specific filing.